Addtl Clinical Trial Site Signed - First Patient Recruited
Filed with ASX · · 2 pages · English
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Non-renounceable rights issue Offer
- Placement & Rights Offer to raise approximately $6 million
- COVID-19 Update
- Successful ISO13485 Surveillance Audit
- Rhythm Successfully Validates Key Biomarker
Later from Rhythm Biosciences
- Revised CEO Contract and LTIP initiated for all employees
- Revised CEO Contract and LTIP for all employees - amended
- Rhythm Successfully Validates Two Adjunct Biomarkers
- New Clinical Trial Site Contracted and Recruiting
- Final Two Adjunct Biomarkers Technically Validated
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences